4 practice questions available

Practice now

Practice this topic with real NCLEX questions.

NurseSavvy Cheat SheetProcedure

Pharmacodynamics

Pharmacodynamics is what the drug does to the body — how it produces its effect at the cellular level — as opposed to pharmacokinetics, which is what the body does to the drug (absorption, distribution, metabolism, excretion). Two patients can have the same blood level yet wildly different effects. Most drugs act by binding receptors (proteins on or inside cells). The four ideas that drive the testable content: receptor action (agonist, antagonist, partial agonist), potency versus efficacy, the dose-response relationship, and the therapeutic index. The clinical payoff is in narrow therapeutic index drugs — digoxin, lithium, warfarin — where the margin between treatment and toxicity is slim, so small dose changes can tip the patient over the edge.

agonist Hallmark
binds and activates the receptor, mimicking the body's signal — albuterol activates beta-2 to relax bronchial smooth muscle
antagonist
binds but blocks activation — propranolol occupies beta receptors so epinephrine can't raise the heart rate
partial agonist
activates submaximally → a ceiling effect — buprenorphine at mu-opioid receptors
competitive antagonist
overcome by increasing agonist concentration
noncompetitive antagonist
cannot be overcome by more agonist — changes clinical management
inverse agonist
produces the opposite effect of the endogenous ligand — not the same as a plain antagonist
potency
how much drug is needed for an effect — lower dose = higher potency
efficacy
the maximum effect achievable regardless of dose
potency and efficacy are independent
a drug can be highly potent but low-efficacy, or the reverse
morphine has higher efficacy than buprenorphine
greater maximal pain relief; buprenorphine's partial agonism caps the response
dose-response curve
effect rises with dose until a plateau
plateau adds toxicity without benefit
past the plateau, more drug only adds harm
therapeutic index Hallmark
ratio of toxic dose to therapeutic dose — the safety margin
narrow therapeutic index drugs
digoxin, lithium, warfarin — slim margin, require closer monitoring
ceiling effect
partial agonists cap out — more dose does not add effect (buprenorphine)
take narrow-margin drugs exactly as prescribed
small dose changes can tip into toxicity
do not increase the dose for more effect
past the ceiling/plateau you add only harm
keep scheduled blood-level checks
digoxin, lithium, warfarin need monitoring
report early toxicity symptoms
even when the dose hasn't changed
Report Nowescalate immediately
toxicity within the listed therapeutic range Hallmark
narrow-TI drugs can be toxic at the upper end — clinical signs override the number
digoxin toxicity at an upper-range level
level 1.9 ng/mL + nausea and visual changes → hold and notify, do not give
do not raise a narrow-TI dose for efficacy
increasing a near-toxic dose worsens toxicity without benefit
do not adjust the dose without an order
independently changing the dose exceeds nursing scope

Clinical Pearl

Potency picks the dose; efficacy picks the drug. A narrow therapeutic index is a tightrope — small dose changes tip the patient from treatment into toxicity, and a level inside the range never overrides the clinical signs in front of you.

NurseSavvy™·nursesavvy.com

Ready to practice this topic?

Get a personalized study plan built around this topic — free to try, no card needed.